CardioDx Hopeful Palmetto Coverage Decision for Corus CAD Test Will Encourage Physician Adoption | GenomeWeb

Originally published August 10.

Medicare contractor Palmetto GBA announced this week that it will cover CardioDx's Corus CAD gene expression test for coronary artery disease, saying that the test meets criteria for analytical validity, clinical validity, and clinical utility as a reasonable and necessary Medicare benefit.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: system to track intron gains and losses, role of RUNX during mitosis, and more.

French officials release a report and move to strength safety measures for clinical trials, ScienceInsider reports.

Researchers find different molecular signatures in cancers from men as compared to those from women, the Wall Street Journal reports.

Researchers trace the deaths of a pair of newborn siblings to a mutation in their LIPT1 genes through whole-exome sequencing, Stat News reports.